A Phase 2 Study of Sacituzumab Govitecan in People with Previously Treated Mesothelioma

Full Title

Purpose

Researchers want to see how well sacituzumab govitecan works in people with pleural mesothelioma. The people in this study have mesothelioma which started in the pleura (the lining of the lung). It is inoperable (cannot be taken out with surgery) or grows after treatment.

Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have pleural mesothelioma that is inoperable or keeps growing even after at least one regimen of treatment.
• Have completed prior anti-cancer medications at least 3 weeks before getting sacituzumab govitecan.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Michael Offin’s office at 646-608-3763.